Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 11/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604813 | 0.90 | USP30 (0.59) | USP30SCN9AGPR119EGFRSRC | |
| SCHEMBL3603888 | 0.89 | USP30 (0.57) | USP30SCN9AGPR119SMARCA2SMARCA4 | |
| SCHEMBL3595734 | 0.89 | USP30 (0.58) | USP30SCN9AMGLLGPR119SMARCA2 | |
| SCHEMBL3606728 | 0.88 | USP30 (0.61) | USP30SCN9AGPR119EGFRSRC | |
| SCHEMBL3605594 | 0.88 | USP30 (0.61) | USP30SCN9AGPR119 | |
| SCHEMBL3597122 | 0.88 | USP30 (0.64) | USP30SCN9AGPR119EGFRSRC | |
| SCHEMBL3601053 | 0.88 | USP30 (0.61) | USP30SCN9AGPR119SMARCA2SMARCA4 | |
| SCHEMBL3610734 | 0.87 | USP30 (0.58) | USP30SCN9AGPR119SMARCA2SMARCA4 | |
| SCHEMBL3601849 | 0.87 | USP30 (0.60) | USP30SCN9AGPR119EGFRSRC | |
| SCHEMBL3609982 | 0.87 | USP30 (0.60) | USP30SCN9AGPR119SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | USP30 4815/4885SCN9A 1132/4885MGLL 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.